The US Department of Agriculture approved the genetically modified purple tomato to extend its shelf life and boost nutritional quality almost 15 years after its development.
According to biochemist Cathie Martin, she and her colleagues at Norfolk Plant Scientists (NPS) have been experimenting with pigment production in flowering plants for over two decades, and they've spent almost 15 months developing the purple tomato.
The NPS has been focusing on anthocyanins, the antioxidant-rich pigments that give blackberries and blueberries their signature shades.
Domesticated tomatoes already have genes to produce anthocyanins, but they are not 'turned on.' By carefully adding two genes, the tomatoes and juice become a rich source of antioxidants, because purple pigments are made in the whole tomato, not just the skins.
While there are already some purple-skinned tomatoes, their pigments mostly stop at the outer layers and don't accumulate in the fruit itself.
The NPS also emphasized that there is increasing evidence to show that antioxidants work much better when consumed within foods.
The USDA Animal and Plant Health Inspection Service (APHIS) reported that the tomato was modified to alter its color and enhance its nutritional quality, adding that the plant is unlikely to pose an increased plant pest risk compared to other cultivated tomatoes.
Nathan Pumplin, the CEO of NPS' US-based commercial business, said they are optimistic that they can begin limited distribution of purple tomatoes in the US by 2023.


NASA and Roscosmos Chiefs Meet in Florida to Discuss Moon and ISS Cooperation
Russian Stocks End Mixed as MOEX Index Closes Flat Amid Commodity Volatility
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
U.S. Stock Index Futures Steady Ahead of Holiday-Shortened Trading Week
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Platinum Surges to Record High as Supply Crunch and Policy Shift Drive Historic Rally
Lab-grown meat: you may find it icky, but it could drive forward medical research
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 



